Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.82 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257143 | 0.94 | L3MBTL1 (0.79) | L3MBTL1FFAR4TSHRMEN1KMT2A | |
| SCHEMBL14570555 | 0.93 | L3MBTL1 (0.77) | L3MBTL1FFAR4TSHRPPARGPPARA | |
| SCHEMBL29335714 | 0.93 | L3MBTL1 (0.77) | L3MBTL1FFAR4TSHRPPARGPPARA | |
| SCHEMBL13450803 | 0.93 | L3MBTL1 (0.77) | L3MBTL1FFAR4TSHRPPARGPPARA | |
| SCHEMBL7691552 | 0.93 | L3MBTL1 (0.77) | L3MBTL1FFAR4TSHRPPARGPPARA | |
| SCHEMBL8357754 | 0.93 | L3MBTL1 (0.77) | L3MBTL1FFAR4TSHRPPARGPPARA | |
| SCHEMBL1806524 | 0.90 | L3MBTL1 (1.00) | L3MBTL1FFAR4TSHRMEN1KMT2A | |
| SCHEMBL31448501 | 0.90 | PPARA (0.65) | L3MBTL1FFAR4PPARAPLA2G4BLMNA | |
| SCHEMBL13940016 | 0.89 | L3MBTL1 (0.66) | L3MBTL1FFAR4TSHRMEN1KMT2A | |
| SCHEMBL29089242 | 0.86 | PLA2G4B (0.68) | L3MBTL1TSHRPPARAPLA2G4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017095898-A1 | USES OF PYRIMIDO-PYRIMIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160348107-A1 | Compositions and Methods for Inhibiting Gene Expression of Hif2alpha | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| US-20160347793-A1 | Biologically Cleavable Tetrapeptide Linking Agents | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| CN-1200915-C | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20040260039-A1 | Process for producing organic compound epoxy resin composition, cured article obtained from the epoxy resin, and semiconductor device obtained with epoxy resin | MITSUI CHEMICALS, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-0950649-B1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | MITSUI CHEMICALS INC (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6130346-A | ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION | MITSUI CHEMICALS, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| CN-1235141-A | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 1999-11-17 | — | — | CN | disclosed |
| EP-0950649-A1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | Mitsui Chemicals, Inc. (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-4563436-A | Catalyst component for α-olefin polymerization and method of producing the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | L3MBTL1 1493/4885FFAR4 125/4885TSHR 681/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | L3MBTL1 4282/4885FFAR4 3714/4885TSHR 2720/4885 |
| US-20160348107-A1 | Compositions and Methods for Inhibiting Gene Expression of Hif2alpha | EPAS1, HIF1AN, EGLN2 | L3MBTL1 1063/4885FFAR4 3499/4885TSHR 3954/4885 |
| US-20160347793-A1 | Biologically Cleavable Tetrapeptide Linking Agents | DNPEP, VIP, ANPEP | L3MBTL1 99/4885FFAR4 4513/4885TSHR 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.